End-of-treatment PET/CT predicts PFS and OS in DLBCL after first-line treatment: results from GOYA
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
End-of-treatment PET/CT predicts PFS and OS in DLBCL after first-line treatment: results from GOYA
Authors
Keywords
-
Journal
Blood Advances
Volume 5, Issue 5, Pages 1283-1290
Publisher
American Society of Hematology
Online
2021-03-03
DOI
10.1182/bloodadvances.2020002690
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Impact of bone marrow biopsy on response assessment in immunochemotherapy-treated lymphoma patients in GALLIUM and GOYA
- (2020) Sarah C. Rutherford et al. Blood Advances
- Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes
- (2018) Bjoern Chapuy et al. NATURE MEDICINE
- Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
- (2018) Roland Schmitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cell-of-origin in diffuse large B-cell lymphoma: findings from the UK's population-based Haematological Malignancy Research Network
- (2018) Daniel Painter et al. BRITISH JOURNAL OF HAEMATOLOGY
- Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma
- (2017) Umberto Vitolo et al. JOURNAL OF CLINICAL ONCOLOGY
- Analysis of prognostic value of complete response by PET–CT and further stratification by clinical and biological markers in DLBCL patients
- (2017) Yusuke Kanemasa et al. MEDICAL ONCOLOGY
- Does end-of-treatment FDG-PET provide any additional prognostic value to the pre-treatment NCCN-IPI score? Reply to Adams and Kwee
- (2016) Mark J. Bishton et al. BRITISH JOURNAL OF HAEMATOLOGY
- Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET/CT and rituximab era: A Danish-Canadian study of 443 patients with diffuse-large B-cell lymphoma
- (2015) Tarec Christoffer El-Galaly et al. AMERICAN JOURNAL OF HEMATOLOGY
- Delineating outcomes of patients with diffuse large b cell lymphoma using the national comprehensive cancer network-international prognostic index and positron emission tomography-defined remission status; a population-based analysis
- (2015) Mark J. Bishton et al. BRITISH JOURNAL OF HAEMATOLOGY
- Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies
- (2015) David W. Scott et al. JOURNAL OF CLINICAL ONCOLOGY
- Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07)
- (2015) Christoph Mamot et al. JOURNAL OF CLINICAL ONCOLOGY
- Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue
- (2014) D. W. Scott et al. BLOOD
- Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group
- (2014) Sally F. Barrington et al. JOURNAL OF CLINICAL ONCOLOGY
- Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
- (2014) Bruce D. Cheson et al. JOURNAL OF CLINICAL ONCOLOGY
- An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era
- (2013) Z. Zhou et al. BLOOD
- Predictive value of interim 18F-FDG-PET/CT for event-free survival in patients with diffuse large B-cell lymphoma homogenously treated in a phase II trial with six cycles of R-CHOP-14 plus pegfilgrastim as first-line treatment
- (2013) Eva González-Barca et al. NUCLEAR MEDICINE COMMUNICATIONS
- The Predictive Value of Interim and Final [18F] Fluorodeoxyglucose Positron Emission Tomography after Rituximab-Chemotherapy in the Treatment of Non-Hodgkin's Lymphoma: A Meta-Analysis
- (2013) Yuyuan Zhu et al. Biomed Research International
- Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP
- (2012) P. Pregno et al. BLOOD
- Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma
- (2011) I. N. M. Micallef et al. BLOOD
- Role of Functional Imaging in the Management of Lymphoma
- (2011) Bruce D. Cheson JOURNAL OF CLINICAL ONCOLOGY
- 18F-FDG PET/CT for Early Response Assessment in Diffuse Large B-Cell Lymphoma: Poor Predictive Value of International Harmonization Project Interpretation
- (2011) A. F. Cashen et al. JOURNAL OF NUCLEAR MEDICINE
- Use of interim [18F]fluorodeoxyglucose-positron emission tomography is not justified in diffuse large B-cell lymphoma during first-line immunochemotherapy
- (2011) M. Christina Cox et al. LEUKEMIA & LYMPHOMA
- Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era
- (2010) Christian Gisselbrecht et al. JOURNAL OF CLINICAL ONCOLOGY
- Time-Dependent Predictive Values of Prognostic Biomarkers With Failure Time Outcome
- (2008) Yingye Zheng et al. JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now